CBI Dimer Antibody-Drug Conjugate Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drug conjugates (ADCs) face challenges in optimizing antibody selection, linker design, and drug stability, which affects their therapeutic efficacy against cancer cells, particularly in targeting specific antigens and achieving effective drug internalization and release.
Innovation Solution
The development of antibody-drug conjugates using 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moieties linked via a specific linker to antibodies, allowing for targeted delivery and release of cytotoxic agents within cancer cells, enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ADCs use standard linker designs and drug moieties, then the structure is simpler and easier to manufacture, but the therapeutic efficacy and targeted delivery to cancer cells is insufficient
Solution Approach 1:
The linker is divided into distinct functional segments: a stretcher unit (Str) for structural support, an optional peptide unit (Pep) for controlled cleavage, and an optional spacer unit (Sp) for positioning. This segmentation allows each component to be optimized independently while maintaining overall functionality, resolving the contradiction between complexity and efficacy.
Solution Approach 2:
The patent introduces a specially designed linker as an intermediary component between the antibody and the CBI dimer drug moiety. This linker mediates the connection by providing stable attachment while enabling controlled drug release through specific cleavage mechanisms, thereby enhancing therapeutic efficacy without requiring direct complex integration of antibody and drug.
2Reliability
If CBI dimer drug moieties are conjugated directly to antibodies without engineered cysteine sites, then the conjugation process is simpler, but the site-specificity and stability of the ADC is reduced
Solution Approach 1:
The patent introduces free cysteine amino acids at specific localized positions on the antibody molecule. These localized cysteine sites provide specific conjugation points with unique chemical properties (thiol groups), enabling site-specific attachment of the linker-drug conjugate. This local modification enhances overall conjugate stability without requiring global changes to the antibody structure.
Solution Approach 2:
The antibody is pre-engineered to contain free cysteine amino acids before conjugation with the linker-drug intermediate. This preliminary introduction of reactive cysteine sites ensures that subsequent conjugation occurs at defined locations with high specificity, improving manufacturing consistency and conjugate stability while simplifying the overall process through predetermined reaction sites.
3Reliability
If standard drug-linker conjugation methods are used, then the manufacturing process is easier, but the controlled release and internalization of the cytotoxic agent is insufficient
Solution Approach 1:
The linker design incorporates dynamic functionality through the optional peptide unit that can be cleaved under specific conditions (such as enzymatic degradation or pH changes) after antibody-antigen binding and internalization. This dynamic characteristic allows the linker to transition from a stable conjugating state to a drug-releasing state, ensuring controlled delivery while maintaining manufacturability through well-established peptide chemistry.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CBI dimer antibody-drug conjugates demonstrate potent anti-tumor activity by effectively targeting and internalizing within cancer cells, leading to enhanced cytotoxicity and improved treatment outcomes for various cancer types.
Implementation Method 1
PBD dimers, where two pyrrolo[2,1-c][1,4]benzodiazepine units are tethered by an alkylene or alkylene-arylene chain are highly efficient interstrand crosslinking agents that react with guanine in the DNA minor groove
Implementation Method 2
Antibody drug conjugates (ADC) are targeted chemotherapeutic molecules combining the properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to antigen-expressing tumor cells
Implementation Method 3
The invention includes 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moieties covalently attached by a linker to form antibody-drug conjugate (ADC) compounds
Data Source
AI summary
The invention provides antibody-drug conjugates comprising an antibody conjugated to a 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimer drug moiety via a linker, and methods of using the antibody-drug conjugates.